Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update

Soyka, Michael

doi:10.1055/a-1298-4508

Cited by 17 publications

(12 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A systematic review on opioid-related treatments and interventions showed that methadone or buprenorphine reduce opioid use and increase adherence to treatment (46). Buprenorphine depot may be an alternative in patients with low adherence to treatment and high risk of diversion (20). The present findings suggest that a rapid transition from methadone treatment to subcutaneous buprenorphine via a single sublingual dose of buprenorphine 4 mg as a "bridge" in incarcerated individuals is possible and can be performed without major discomfort for the patient.…”

Section: Discussionmentioning

confidence: 66%

“…A recent meta-analysis showed a median retention rate of 57% at 12 months and of 38.4% after 3 years (19). The introduction of novel long-acting depot or implant formulations may lower the dropout rate (20). The transition from a full opioid agonist like methadone to a partial agonist like buprenorphine will induce precipitated withdrawal (21,22).…”

Section: Introductionmentioning

confidence: 99%

“…Recently, three novel long-acting buprenorphine medications have been approved for use in some countries for the treatment of OUD (20). CAM 2038 (Buvidal) is a s.c. depot buprenorphine injection approved in Europe and currently under consideration in the US for approval by FDA.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting – a case series

Soyka

Gross

2021

The American Journal of Drug and Alcohol Abuse

Self Cite

View full text Add to dashboard Cite

Background: Methadone, a full opioid agonist, and buprenorphine, a partial agonist at the opioid receptor, are established first-line medications for opioid maintenance therapy. Transition from methadone to sublingual buprenorphine may precipitate withdrawal and is usually performed only in patients on low dose of methadone (<30-40 mg). Transition from methadone to a novel subcutaneous buprenorphine depot (Buvidal) has not been previously described. Objectives: To test the hypothesis that a rapid transition from methadone to buprenorphine depot after a single dose of buprenorphine 4 mg sublingual is safe and well tolerated. Methods: Retrospective chart analysis of a case series of seven opioid users under custodial setting (prison) who were switched from methadone to buprenorphine depot (initial dose 16 mg weekly subcutaneously) after an initial test dose of buprenorphine 4 mg sublingual within 48 hours. Results: Clinical data indicate that a rapid transition from methadone to depot buprenorphine is feasible (six patients within 48 hours, one within 4 days). All patients were successfully switched to buprenorphine depot and the transfer period was completed without dropouts or major medical problems. Further dose adjustments were performed in 4 of 7 patients. Conclusions: Transition of opioid users from methadone to buprenorphine depot is feasible and safe via 4 mg buprenorphine sublingual. This procedure may facilitate induction of buprenorphine depot formulations in patients treated with methadone.

show abstract

Section: Discussionmentioning

confidence: 66%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting – a case series

Soyka

Gross

2021

The American Journal of Drug and Alcohol Abuse

Self Cite

View full text Add to dashboard Cite

show abstract

“…The combination of buprenorphine and naloxone has not changed this situation Kelty et al [34]. The recently introduced or emerging new long-acting buprenorphine (depot or implant) formulations are a major progress in OMT [35][36][37]. There will be weekly and monthly s.c. buprenorphine injections, or even 6-month depot formulations.…”

Section: Discussionmentioning

confidence: 99%

Recent Advances in the Treatment of Opioid Use Disorders

Soyka¹

2020

TNN

Self Cite

View full text Add to dashboard Cite

For pharmacotherapy of opioid use disorders treatment with oral methadone or sublingual buprenorphine are established first-line treatments. Recently three novel long-acting buprenorphine depot or implant formulations have been studieD and in part approved for treatment of opioid use disorders: for subcutaneous weekly and monthly application the depot formulations CAM 2038 [Buvidal®], the monthly depot formulation RBP-6000 [Sublocade™] and the six-month buprenorphine implant [Probuphine™]. The pharmacology and efficacy of these novel medications will be reviewed and discussed

show abstract

“…Drug dosing, age, other substance use (heroin, cocaine) and negative attitudes toward treatment are of relevance in this respect ( O’Connor et al, 2020 ). Recently several long-acting buprenorphine formulations have been tested, approved, and in part introduced into clinical practice ( Soyka, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review

Soyka¹

2021

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Methadone, a full opioid agonist at the mu-, kappa-, and delta-receptor, and buprenorphine, a partial agonist at the mu receptor, are first-line medications in opioid maintenance treatment. Transition from methadone to buprenorphine may precipitate withdrawal, and no accepted algorithm for this procedure has been developed. Current treatment strategies recommend transfer from methadone to buprenorphine predominantly in patients at low doses of methadone (30–40 mg/day). There are some reports indicating that transition from higher doses of methadone may be possible. A number of dosing strategies have been proposed to soften withdrawal symptoms and facilitate transfer including use of other opioids or medications and especially microdosing techniques for buprenorphine. The case series and studies available thus far are reviewed.

show abstract

Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update

Cited by 17 publications

References 62 publications

Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting – a case series

Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting – a case series

Recent Advances in the Treatment of Opioid Use Disorders

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review

Contact Info

Product

Resources

About